Eloralintide and Tirzepatide: What EloraTZP Research Shows
Published · Page updated
Bookmark this page
Save this article in your browser so you can find it again:
- Computer: Press Ctrl+D (Windows) or ⌘+D (Mac).
- iPhone or iPad: In Safari, tap Share, then Add Bookmark.
- Android: In Chrome, open the menu and tap the star.
Other browsers may use a different menu.
EloraTZP is an investigational combination of eloralintide and tirzepatide. Its phase 2b study examined weight and glucose outcomes in adults with overweight or obesity and type 2 diabetes. The reported benefits need to be read alongside treatment discontinuations and the limits of sponsor-reported evidence. Original sponsor results.
Publisher disclosure: Bio Research LLC operates Bio Peptides Labs and sells research materials. This is commercially interested, AI-assisted editorial content, not an independent scientific review. Sponsor announcements, a conference presentation and the trial record were checked November 16, 2026. A full peer-reviewed report of this combination trial was not identified in the bounded search. A focused November 19 PubMed search pairing eloralintide or its research code with tirzepatide terms returned no records; unpublished or differently indexed work could be missed. No catalog product is represented as the trial material or as a validated human-use combination.

What are eloralintide and tirzepatide?
Eloralintide is being developed as a selective amylin-receptor agonist. Tirzepatide acts at GIP and GLP-1 receptors. The study tested separate administration of the agents; the name EloraTZP should not be read as proof that any similarly named mixture reproduces the studied product. EASD presentation.
A mechanism explains why a combination might be investigated. It cannot settle whether the added benefit outweighs harms. That requires evidence from the specific combination, population and comparator.
What was the phase 2b study?
The registered study, NCT06603571, enrolled 367 adults into multiple randomized groups over 48 weeks. Participants had type 2 diabetes as well as overweight or obesity. The program compared combination groups, individual agents and placebo. Its population should not be described simply as everyone seeking weight loss. Trial record.
The original results were announced September 30, 2026. Lilly's November 14 release discussed conference coverage of this same program. We treat November as a research update, rather than a second trial confirming the first. November announcement.
What did the sponsor report?
In its efficacy analysis, Lilly reported weight reduction of up to 23.3% in a combination group, compared with 14.8% for tirzepatide and 3.0% for placebo at 48 weeks. “Up to” refers to a particular studied group, not the average across all combinations. September results announcement.
The conference presentation describes efficacy estimates using observations before treatment discontinuation. Its safety analysis includes treated participants regardless of adherence. The two analyses answer different questions, so a headline weight estimate alone cannot describe the experience of everyone randomized. Primary presentation.
Question | Evidence to examine |
|---|---|
Did adding eloralintide improve outcomes? | The prespecified combination-versus-comparator results and uncertainty |
Could participants continue treatment? | Discontinuations, their reasons and which group they occurred in |
Does the result apply elsewhere? | Diabetes status, eligibility, follow-up and the actual materials studied |
Why treatment discontinuation matters
The sponsor reported adverse-event discontinuation rates of 10.8%–27.0% across combination groups, versus 2.9% with tirzepatide and 16.7% with placebo. These findings prevent a simple conclusion that adding another mechanism is automatically better tolerated. Original safety summary.
The presentation lists gastrointestinal symptoms among adverse events and includes pooled safety totals across all study groups. A pooled total cannot be assigned to the combination alone. Our article does not claim that all serious events were caused by treatment or that absence of a proven causal link establishes safety. Conference safety data.
What comes next in EloraTZP research?
The registry lists AMPLIFY-1, a phase 3 study in adults with obesity without type 2 diabetes. It plans to compare combination groups with each individual agent and placebo, with percentage change in body weight at week 100 as its primary outcome. Its estimated enrollment is 2,115; that is a target, not a count of participants already enrolled.
When checked November 19, 2026, the record listed the study as not yet recruiting, with an estimated December 2026 start and no posted results. The registry was last updated November 17; status and estimated dates can change. This proposed study is not a completed finding, and its population differs from the phase 2b diabetes study.
What should further research resolve?
We would look for a complete peer-reviewed report with group-specific harms, missing-data methods and prespecified comparisons. Longer studies should examine durability and outcomes that matter beyond weight alone. Different populations require their own evidence.
These are editorial evaluation criteria. They are not a proposed personal regimen or a claim that Bio Peptides Labs is sponsoring such work.
Is EloraTZP the same as CagriSema?
No. The named components differ. Our CagriSema REDEFINE 9 guide describes the separate cagrilintide-semaglutide study. Percentages from different trials should not be used as a head-to-head ranking.
Does this validate other peptide stacks?
No. Controlled combination development does not validate combinations of different compounds or research-labeled materials. Read the retatrutide combination-research guide for the evidence gaps.
How can readers evaluate the next announcement?
Check whether it contains new participants, longer follow-up, a new analysis of existing data or a new publication of earlier results. Then compare its methods with the registered study and use our study-reading guide to separate endpoints from broader claims.
For context on research-labeled incretin products, see FDA's GLP-1 information.
References
On November 19, 2026, we rechecked the phase 2 and phase 3 registry records and the sponsor’s phase 2 weight and discontinuation summaries, and ran the focused PubMed search described above. The conference presentation and November announcement retain their earlier access scope. No full phase 2 journal report or participant-level dataset was reviewed.
